Key Takeaways
- • Torrent Pharmaceuticals is in advanced discussions with CVC Capital Partners to raise $1.2–$1.5 billion in equity funding for a $7 billion acquisition of Cipla's promoter stake, with a target close by end of September 2023.
- • Torrent is assembling a multi-layered financing structure: equity from CVC (potentially scalable to $2.25 billion), mezzanine debt of Rs 8,300–9,000 crore (~$1 billion–$1.1 billion) from Brookfield, and potential co-investment from Bain Capital.
- • The Mehta family (Sudhir and Samir), which holds 71.25% of Torrent, plans to dilute their stake to leverage promoter shares as collateral for loans, retaining an estimated 48–63% post-acquisition.
- • Torrent has approached multiple PE funds to secure capital, with CVC emerging as the preferred lead partner over Bain Capital, reflecting strategic confidence in European backing for a domestic pharma consolidation play.
- • The transaction hinges on open offer subscription levels, with Torrent targeting $750 million to $2.25 billion in equity depending on market uptake and domestic shadow bank/mutual fund participation.
Summary
Torrent Pharmaceuticals is pursuing an ambitious pharmaceutical consolidation strategy, entering advanced negotiations with European private equity firm CVC Capital Partners to secure at least $1.2–$1.5 billion in equity capital for a $7 billion acquisition of Cipla's promoter holding. According to reporting from The Economic Times, Torrent has positioned CVC as its preferred lead equity partner, though discussions with Bain Capital continue as a potential co-investor option.
The financing structure reflects a sophisticated multi-tranche capital stack. Beyond equity, Torrent is simultaneously negotiating with Brookfield to secure Rs 8,300–9,000 crore in mezzanine debt—a lever designed to optimize returns and reduce equity dilution. The promoter family, Sudhir and Samir Mehta, currently controls 71.25% of Torrent and intends to reduce this stake through leverage, using shares as collateral for loans in a non-disposable undertaking (NDU) arrangement. Post-acquisition modeling suggests the Mehta family would retain 48–63% ownership depending on final capital structure.
Deal timing is aggressive, with Torrent targeting a funding close by end of September 2023. However, the ultimate equity raise—estimated between $750 million and $2.25 billion—remains fluid, contingent on the subscription level of the open offer to Cipla shareholders. Sources indicate both CVC and Brookfield have capacity to increase commitments substantially if Torrent cannot source additional capital from domestic shadow banks and mutual funds, underscoring the strategic importance of the transaction and the availability of alternative funding routes in India's private credit ecosystem.
This transaction represents a significant consolidation moment in Indian pharmaceuticals, with Torrent positioning itself as a consolidator of peer assets through leveraged equity partnership and structured debt financing.
The financing structure reflects a sophisticated multi-tranche capital stack. Beyond equity, Torrent is simultaneously negotiating with Brookfield to secure Rs 8,300–9,000 crore in mezzanine debt—a lever designed to optimize returns and reduce equity dilution. The promoter family, Sudhir and Samir Mehta, currently controls 71.25% of Torrent and intends to reduce this stake through leverage, using shares as collateral for loans in a non-disposable undertaking (NDU) arrangement. Post-acquisition modeling suggests the Mehta family would retain 48–63% ownership depending on final capital structure.
Deal timing is aggressive, with Torrent targeting a funding close by end of September 2023. However, the ultimate equity raise—estimated between $750 million and $2.25 billion—remains fluid, contingent on the subscription level of the open offer to Cipla shareholders. Sources indicate both CVC and Brookfield have capacity to increase commitments substantially if Torrent cannot source additional capital from domestic shadow banks and mutual funds, underscoring the strategic importance of the transaction and the availability of alternative funding routes in India's private credit ecosystem.
This transaction represents a significant consolidation moment in Indian pharmaceuticals, with Torrent positioning itself as a consolidator of peer assets through leveraged equity partnership and structured debt financing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.